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Abstract
Background: Frontotemporal Lobar Degeneration (FTLD) thus recently renamed, refers to a
spectrum of heterogeneous conditions. This same heterogeneity of presentation represents the
major methodological limit for the correct evaluation of clinical designation and brain functional
correlates. At present, no study has investigated clinical clusters due to specific cognitive and
behavioural disturbances beyond current clinical criteria.
The aim of this study was to identify clinical FTLD presentation, based on cognitive and behavioural
profile, and to define their SPECT functional correlations.
Methods: Ninety-seven FTLD patients entered the study. A clinical evaluation and standardised
assessment were preformed, as well as a brain SPECT perfusion imaging study. Latent Profile
Analysis on clinical, neuropsychological, and behavioural data was performed. Voxel-basis analysis
of SPECT data was computed.
Results: Three specific clusters were identified and named "pseudomanic behaviour" (LC1),
"cognitive" (LC2), and "pseudodepressed behaviour" (LC3) endophenotypes. These
endophenotypes showed a comparable hypoperfusion in left temporal lobe, but a specific pattern
involving: medial and orbitobasal frontal cortex in LC1, subcortical brain region in LC2, and right
dorsolateral frontal cortex and insula in LC3.
Conclusion: These findings provide evidence that specific functional-cluster symptom relationship
can be delineated in FTLD patients by a standardised assessment. The understanding of the
different functional correlates of clinical presentations will hopefully lead to the possibility of
individuating diagnostic and treatment algorithms.
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Frontotemporal Lobar Degeneration (FTLD) refers to a
spectrum of heterogeneous conditions [1]. The disease
designation and the disease concept were renamed in the
past few years as different clinical criteria have been
evolved over time. Until now, all these syndromes have
been recognised to present with cognitive and language
disturbances, personality changes and behavioural symp-
toms, including different clinical and anatomical condi-
tions. Primary Progressive Aphasia (PPA), also called
progressive nonfluent aphasia (PNFA), typically occurs
with dominant frontotemporal atrophy [2,3]. These
patients do not initially demonstrate behavioural abnor-
mality. If the dominant temporal lobe is involved, FTLD
presents with anomia, and the result is often impairment
in language comprehension and loss of meaning, called
Semantic Dementia (SD), which is often associated with
behavioural abnormalities [1]. When behavioural abnor-
malities are the presenting feature, usually with nondom-
inant temporal and frontal atrophy, the label
"behavioural variant" (bvFTD) is used [4]. The recogni-
tion of a genetic and clinical overlap of FTLD with Corti-
cobasal Degeneration (CBD) and Progressive
Supranuclear Palsy (PSP) suggested the inclusion of these
relatively rare conditions under the same nosographic
label of FTLD [5,6].
Therefore, different presentations were separated into
independent entities, creating a terminological prolifera-
tion and multiplying rare diseases. The classification of
these diverse conditions remains controversial, some
groups perceive FTLD as a unitary continuum whereas
others describe more discrete syndromes [5,7].
Pathological fractionation did not lag behind, as histo-
chemistry and molecular biology yielded new features [8].
Because of excessive deposits of hyperphosphorylated tau
in affected neurons and glia, the underlying pathology of
FTLD was regarded as a tauopathy. Paradoxically, the gen-
eral label of tauopathy has been expanded to include cases
in which tau was not found in the brain, and the vast
majority of FTLD pathology is actually recognized by
ubiquitin positive and tau negative inclusions.
FTLD conditions, however, have more in common than
previously recognised, and the term Pick's Complex was
chosen to signify their cohesion [5].
In fact, an integrative approach based on clinicopatholog-
ical correlation suggests that not only the bvFTD, SD, and
PNFA overlap clinically and pathologically, but the
extrapyramidal component, i.e. CBD and PSP, should be
considered part of an overall entity named FTLD [1,5]. All
these syndromes were recognised to overlap throughout
disease progression, and it was recently demonstrated that
there is a convergence of the syndromes in the course of
the disease [9].
Brain imaging techniques have been successfully used to
characterise the different syndromes, allowing us to
explore the involved neural systems, and helping us in
comprehend their pathogenetic mechanisms [6,10,11].
The question that remains opens, however, is whether a
single neural network underscoring FTLD or different
entities might be discriminated by structural or functional
neuroimaging. The further problem in evaluating FTLD
patients is that, in most cases, more than one behavioural
or cognitive symptom occurs in the same patient [12]. In
addition, the use pre-defined clinical criteria aimed to ver-
ify such imaging data may imply a risk of circularity.
At present, clinical clusters might provide the opportunity
to identify specific cognitive and behavioural patterns
beyond current clinical criteria.
With this aim in mind, we applied Latent Profile Analysis
(LPA), a latent variable model that is used to detect sub-
groups or syndromes based on the observed relationship
between chosen continuous indicators or symptoms [13].
LPA is here employed to rationalise the large clinical and
neuropsychological data set with an open approach,
allowing us to reveal discrete clinical presentation.
Once the data-driven classification has been formed, its
coherence was verified by functional neuroimaging infor-
mation.
Methods
Subjects
This study is part of an ongoing research program aimed
at evaluating the core feature of FTLD. Patients who met
the Neary [14] and McKhann [15] criteria for FTLD were
consecutively recruited from March 2003 through July
2005 from the "Center for Aging Brain and Neurodegen-
erative Diseases", University of Brescia, Italy.
All subjects underwent a somatic and neurological evalu-
ation, and routine laboratory examination, a brain struc-
tural Magnetic Resonance Imaging (MRI) study, and a
brain functional Single Photon Emission Tomography
(SPECT) study.
The diagnostic assessment involved a review of full medi-
cal history, a semi-structured neurological examination,
and a complete mental status evaluation by two inde-
pendent and experienced reviewers (B.B., A.P.). Only
patients with full consensus agreement by the reviewers
were enrolled.Page 2 of 12
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scale of Unified Parkinson Disease Rating Scale (UPDRS)
III [16]. Global cognitive function assessment was made
according to a standardized battery, including the Mini-
Mental State Examination (MMSE) [17]. The neuropsy-
chological assessment was made with the following tests:
Raven Colored Progressive Matrices [18], Controlled Oral
Word Association Test and Category Fluency [19], Clock
Drawing Test [20], Rey Complex Figure Copy and Recall
[21], Story Recall Test [22], Digit Span [23], Trail Making
Test A and B [24], Token Test [25], and De Renzi Imitation
Test [26]. Instrumental Activities of Daily Living (IADL)
[27], and Basic Activities of Daily Living (BADL) [28] were
assessed as well. Behavioural and psychiatric disturbances
were evaluated by Neuropsychiatry Inventory (NPI) [29],
and Frontal Behavioual Inventory (FBI) [30].
Patients considered to have a positive family history were
those who had a first-degree relative with dementia, Par-
kinsonism, or motor neuron disease. No patients belong-
ing to the same family were included.
All participants were made fully aware of the research
goals, and the signature of an informed consent was
required from all subjects. The work was conducted in
accordance with local clinical research regulations and in
conformity with the Helsinki Declaration.
Inclusion criteria
The Neary [14] and McKhann criteria [15] for FTLD were
fulfilled by all subjects. In particular, bvFTD was defined
by character change and disorder of social conduct. SD
was defined by a prominent comprehension disorder
(impaired understanding of word meaning and/or object
identity), difficulty in naming, and asking for the name of
nouns and objects. PNFA was diagnosed when the first
symptom was an isolated disorder of expressive language
when other aspects of cognition and daily living functions
were relatively well preserved. CBD exhibited unilateral
rigidity and apraxia, some of them having 'alien hand'. In
these patients the extrapyramidal syndrome developed
first and was followed by cognitive changes. PSP showed
vertical gaze palsy, repetitive falls, axial rigidity and pseu-
dobulbar palsy; a poor response to L-dopa treatment was
counted as an additional inclusion criterion.
In FTLD patients, an adjunctive inclusion criterion was an
initial diagnosis confirmation after the patient had been
followed periodically for a 1.5 year period.
Exclusion criteria
Stringent exclusion criteria were applied as follows: a) cer-
ebrovascular disorders, previous stroke, hydrocephalus,
and intra-cranial mass documented by MRI; b) a history
of traumatic brain injury or another neurological disease
(e.g. seizures, choreoathetosis, cerebellar ataxia); c)
another extrapyramidal syndrome (e.g. Parkinson disease,
Lewy Body Disease, Vascular Parkinsonism, Multiple Sys-
temic Atrophy) according to current clinical criteria; d)
significant medical problems (e.g. poorly controlled dia-
betes or hypertension; cancer within the past 5 years; clin-
ically significant hepatic, renal, cardiac, or pulmonary
disorders); e) major depressive disorder, bipolar disorder,
schizophrenia, substance abuse disorder, or mental retar-
dation according to criteria of the DSM-IV.
99mTc-ECD SPECT acquisition
For brain functional data comparisons, a group of healthy
subjects (n = 15, mean age ± SD = 56.3 ± 15.4) were
recruited among patients' spouses or relatives and were
included as normal controls. They were interviewed,
assessed for neurological or cognitive dysfunction, evalu-
ated for diseases that were exclusion criteria for the
patients group, and underwent a brain SPECT study.
Both patients and controls were administered an intrave-
nous injection of 1110 MBq 99mTc-ECD (ethylcysteinate
dimer, Neurolite, Bristol-Myers Squibb Pharma) in a rest
condition, lying supine in a quiet, dimlylit room.
All subjects were imaged using a dual-head rotating
gamma camera (VG MILLENIUM GE) fitted with a low
energy, high-resolution collimator, 30 minutes after intra-
venous injection of 99mTc-ECD.
A 128 × 128 pixel matrix was used for image acquisition
with 120 views over a 360° orbit (in 3° step) with a pixel
size and slice thickness of 1 mm, in 27 min or more if total
counts were lower than 5 × 106. Image reconstruction was
performed by a ramp filtered-back projection and three-
dimensionally smoothed with a Metz filter (order 3,
enhancement 1.24, FWHM 6.7 mm, cut-off 0.61 cycles
cm-1). The reconstructed images were corrected for
gamma ray attenuation using the Chang method (attenu-
ation coefficient: 0.11 cm-1).
Image pre-processing and analysis
Statistical Parametric Mapping (SPM2, Welcome Depart-
ment of Cognitive Neurology, University College, Lon-
don), and Matlab 6.1 (Mathworks Inc., Sherborn, MA)
were used for image pre-processing. Images were spatially
normalized to a reference stereotactic template (Montreal
Neurological Institute, MNI), and smoothed by a Gaus-
sian kernel of 8 × 8 × 8 mm FWHM SPECT data analysis
was performed in blind to clinical and genetic diagnosis.
Global differences in the distribution, and the effect of age
on the tracer's uptake were covariated out for all voxels.
Comparisons across the different groups were made using
t-statistics with appropriate linear contrasts [31]. We con-Page 3 of 12
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0.001.
We performed the following group comparisons: (1) each
FTLD group, i.e. bvFTD, SD, PNFA, PSP and CBD vs. con-
trols, in order to explore the hypoperfusion patterns
according to clinical diagnosis, and (2) FTLD patients
belonging to each Latent Class group vs. controls, to
explore the hypoperfusion patterns according to latent
classes.
Statistical analysis
Latent Profile Analysis (LPA) was used to determine the
number and composition of groups in which participants
aggregated on the basis of their indicator values.
LPA, as Latent Class Analysis (LCA), is a latent variable
model that serves to cluster subjects. LCA explains the
clustering of cases, based on the relationship of a set of
observed (manifest) categorical indicators by assuming
that the patterns of values are determined by a latent
(unobserved) categorical variable. Inversely, LPA allows
continuous indicators to be present. For both, the
number of categories of the latent variables (i.e. number
of latent classes) represents the number of different clus-
ters in subjects. In the classic form of the LPA used here,
observed continuous indicators within each latent class
were assumed to be uncorrelated. In other words, the
model supposes that the correlation matrix between con-
tinuous outcomes is due to unobserved heterogeneity, i.e.
the pairwise relationships between the continuous out-
comes are due to mixing an unknown number of different
classes of individuals, each having unrelated outcomes.
This is also referred as conditional independence
assumption, with the idea that if a sufficient number of
classes is introduced, the conditional independence is
more likely to hold. Thus, the latent categorical variable
captures population heterogeneity, and the parameters of
the model are: latent class prevalences, indicator means
within latent classes, and indicator variances common to
all latent classes.
We performed a sequence of five LPA models, from one to
five classes, with varying across-class indicator means, and
across-class common indicator variances. Neuropsycho-
logical performances (MMSE, Raven Colored Progressive
Matrices, Controlled Oral Word Association Test, Cate-
gory Fluency, Clock Drawing Test, Rey Complex Figure
Copy and Recall, Story Recall Test, Digit Span, Trail Mak-
ing Test A and B, Token Test, and De Renzi Imitation
Test), functional impairment (IADL, BADL), and behav-
ioural disturbance (NPI, FBI) and motor impairment
(UPDRS-III) were introduced in the LPA as observed con-
tinuous indicators. UPDRS-III and De Renzi Imitation
Test were excluded because they resulted uncorrelated
with the previous variables in a preliminary descriptive
data analysis.
Model parameters were estimated using Maximum Likeli-
hood Estimator (MLE) based on the Expectation Maximi-
zation (EM) algorithm. The Akaike's Information
Criterion (AIC = -2 × model log-likelihood + 2 × number
of model parameters) and Bayesian Information Criterion
(BIC = -2 × model log-likelihood + log(n) × number of
model parameters) were computed to compare such com-
peting models, and the selected model was the one mini-
mizing either AIC or BIC [32].
Using the entropy index, the quality of the resulting clas-
sification was also evaluated in terms of the separation of
the latent classes. Entropy denotes how possible it is to
predict class membership given the observed indicators.
Values range from 0 to 1, and high values (>0.90) indicate
that the latent classes are highly discriminative.
The statistical significance of the parameter estimates were
evaluated by t-tests (= parameter/standard error) consid-
ering robust standard errors. Multiple comparisons proce-
dures based on the Fisher's Least Significant Difference
(LSD) testing of across-class mean estimates were used to
select discriminative indicators. The significance level was
established at P < 0.05, two-sided.
All models were fit using Mplus software (version 3.13 for
Windows), and full details of the computing approach
can be found in Muthèn & Muthèn user's guide [33].
Results
Subjects
Ninety-seven patients entered the study. Demographic
and clinical characteristics according to clinical diagnosis
are reported in Table 1. Overall, FTLD patients were mild
for global cognitive decline. BvFTD diagnosis was the
most prevalent (42.2%), SD and PNFA diagnoses were
less prevalent (5–6%). BvFTD showed higher behavioural
disturbances (NPI and FBI-AB) compared to SD and PNFA
patients, who had a different pattern of behavioural dis-
turbances (as illustrated by high loadings in FBI-A but low
scores in FBI-B); whilst CBD and PSP, as expected, showed
the worst motor impairment.
Neuropsychological profile in bvFTD, SD, PNFA, CBD,
and PSP patients, and the number of patients with patho-
logical scores in each group, is reported in Table 2. Neu-
ropsychological tests which resulted pathological in more
than 50% of cases, according to Italian normative data,
are highlighted: bvFTD showed greater behavioural dis-
turbances, and SD were more impaired in verbal and non-
verbal memory (Short Story and recall of Rey Complex
Figure), category fluency, and executive functions (TrailPage 4 of 12
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icits (verbal and category fluency) and were more
impaired in visuo-spatial skills (Trail Making A); while
CBD and PSP showed deficits in visuo-spatial skills (copy
of Rey Complex Figure and Trail Making A). Pathological
scores of the De Renzi Imitation test were found in 43.8%
of CBD patients because of the mild stage of the disease.
Functional correlates of clinical diagnosis
SPM2 was applied to SPECT scans, which were sub-
grouped according to clinical diagnosis (total number =
50; bvFTD = 20, SD = 3, PNFA = 2, CBD = 11, and PSP =
14). As reported in Figure 1, bvFTD showed hypoper-
fusion in medial frontal cortex (x, y, z = 6, 16, -12; T =
4.35, cluster size = 845; and -4,32,12; T = 3.97, cluster size
= 834) and left temporal cortex (-16,12,-36; T = 3.92, clus-
ter size = 347); SD patients had significant hypoperfusion
in left temporal pole (-44,-4,-32; T = 4.87, cluster size =
1162); PNFA showed an involvement of both left frontal
cortex (-32,54,20; T = 4.42, cluster size = 230) and left
inferior temporal gyrus (-58,-32,-20; T = 4.09, cluster size
= 167); PSP patients had significant involvement in
medial frontal cortex (-2,30,16; T = 4.23, cluster size =
3846), dorsolateral frontal cortex (-48,18,24; T = 4.41,
cluster size = 226) and basal ganglia and mesencephalon;
CBD patients showed hypoperfusion in left inferior pari-
etal lobe (-46,-52,28; T = 3.49, cluster size = 160), right
superior temporal gyrus (36,-30,8; T = 3.77, cluster size =
141), and left uncus and parahippocampal region (-18,2,-
32, T = 4.02; cluster size = 312).
Latent Profile Analysis
LPA models were fitted with 16 variables, that had from 1
to 5 LCs. Among 97 FTLD patients, 5 were excluded
because of missing values. The fit statistics suggested that
the model with 4 LCs had the best fit, producing mini-
mum AIC and BIC values, and having the highest separa-
tion of the LCs evaluated by entropy measure (see Table
3). The second best model was the LPA model with 3 LCs.
This model was preferred because the estimated mean
profiles were more interpretable than those with 4 LCs.
Additionally, the reduction in BIC statistic from 3 to 4
classes was close to zero [BIC(4) = 5401 vs. BIC(3) =
5407], and the entropy measures were close to 1 and com-
parable [entropy (4) = 0.963 vs. entropy (3) = 0.951].
Table 4 shows the parameter estimates for the 3 selected
LCs. These parameters represent the latent classes' preva-
lences, the latent class specific mean profiles and the com-
mon variances of 16 variables considered in the LPA
model.
Of the total sample, 18 (18.5%) patients belonged to
Latent Class 1 (LC1), 41 (42.3%) to Latent Class 2 (LC2),
and 38 (39.2%) to Latent Class 3 (LC3).
As shown in Figure 2, these three LCs were significantly
separated from each other.
Using statistically significant pairwise mean differences
provided by multiple comparisons procedure which was
Table 1: Demographic and clinical characteristics of included FTLD patients.
Diagnosis bvFTD SD PNFA CBD PSP
N 41 5 6 16 29
Age, years 66.8 ± 7.2 69.0 ± 9.0 61.3 ± 7.3 61.6 ± 7.7 72.7 ± 5.2
Gender, F% 48.8 (20) 80 (4) 83.3 (5) 50 (8) 41.4 (12)
FH* 36.4 (12) 0 (0) 40 (2) 18.3 (3) 23.1 (6)
Education, years 7.1 ± 3.0 10.0 ± 3.7 6.8 ± 3.2 8.5 ± 4.8 7.2 ± 4.5
Age at onset, years 63.7 ± 7.8 67.2 ± 9.1 56.6 ± 3.2 61.1 ± 5.4 70.5 ± 4.9
UPDRS-III 9.2 ± 8.7 3.2 ± 3.1 6.1 ± 6.6 18.1 ± 10.9 22.7 ± 11.8
MMSE 21.6 ± 5.8 21.0 ± 6.4 18.6 ± 6.8 22.6 ± 4.5 24.7 ± 4.0
NPI 19.9 ± 14.1 12.0 ± 9.7 15.1 ± 10.5 8.0 ± 9.2 9.8 ± 9.8
FBI-A 12.0 ± 7.7 11.8 ± 8.1 13.6 ± 8.9 8.0 ± 8.4 4.8 ± 6.5
FBI-B 8.1 ± 6.7 4.8 ± 4.4 4.5 ± 5.3 1.6 ± 2.1 2.4 ± 3.9
FBI-AB 21.8 ± 15.5 16.6 ± 10.7 19.0 ± 15.0 13.6 ± 8.6 7.3 ± 8.8
BADL 0.7 ± 1.5 0.4 ± 0.8 0.0 ± 0.0 0.5 ± 0.9 0.8 ± 1.4
IADL 2.3 ± 2.7 2.2 ± 2.6 1.6 ± 2.6 0.7 ± 1.5 1.3 ± 2.0
bvFTD: behavioural variant of Frontotemporal Dementia; SD: Semantic Dementia; PNFA: Slowly Progressive Aphasia; CBD: Corticobasal 
Degeneration; PSP: Progressive Supranuclear Palsy; N: number; F: female; FH: Family History; UPDRS: Unified Parkinson Disease Rating Scale; 
MMSE: Mini-Mental State Examination; NPI: Neuropsychiatry Inventory; FBI: Frontal Behavioural Inventory; BADL: Basic Activities of Daily Living; 
IADL: Instrumental Activities of Daily Living.
Number of subjects between brackets. *missed values are due to unknown FH.Page 5 of 12
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testing, the latent classes are described as follows: LC1
denoted subjects with high means on behavioural distur-
bances (FBI-A, FBI-B, and NPI) and daily living functional
impairment (BADL, IADL) compared to the other two
classes. LC3 was defined by subjects with fewer cognitive
disturbances measured by this neuropsychological assess-
ment compared to those in LC1 and LC2. Finally, LC2 rep-
resented the patients with fewer behavioural disturbances
but an equal cognitive profile compared to LC1 patients.
In addition, LC2 shared identical behavioural deficits, but
have more pronounced cognitive impairment than LC3
patients.
In clinical terms, behavioural disturbances, such as disin-
hibition and abnormal social conduct (as demonstrated
by high FBI-B scores), characterized LC1 patients. LC2
patients showed a profile of substantial cognitive impair-
ment with in particular a poor performance in the Trail
Making B test. LC3 patients showed less cognitive impair-
ment than the other two classes, and behavioural distur-
bances similar to LC2 patients. In order to better define
the behavioural aspect of LC3 patients, we therefore con-
sidered the subscores of the behavioural profile. We found
that LC3 and LC2 mainly differed for a greater prevalence
of depressive symptoms in the former (data not shown).
Thus, we adopted the following clinical labels for the 3
LCs: "pseudomanic behaviour" endophenotype for LC1
and "pseudodepressed behaviour" endophenotype for
LC3 (see reference 34); LC2 was named as "cognitive"
endophenotype.
Functional correlates of Latent Classes
Functional SPECT data were then analysed according to
the LCs. Fifty patients out of 97 underwent a SPECT scan.
Nine patients belonging to LC1, 17 belonging to LC2, and
24 belonging to LC3 were compared to control subjects,
respectively.
As shown in Figure 3, distinct functional patterns were
found in LC1, LC2, and LC3 subgroups.
Comparisons of LC1 ("pseudomanic behaviour" endo-
phenotype) vs. controls showed significant hypoperfusion
in medial frontal cortex (x, y, z = -8, 50, 16; T = 5.19, clus-
ter size = 1167), in the orbitobasal frontal cortex (0,12 -
16; T = 4.52, cluster size = 871), and in left temporal pole
(-38,14,-24; T = 3.82, cluster size = 171).
LC2 ("cognitive" endophenotype) vs. controls showed
comparable hypoperfusion in the left temporal pole (-14,-
4,-24; T = 4.76, cluster size = 457) and in subcortical brain
region (-2,-6,-12; T = 4.76, cluster size = 457).
LC3 ("pseudodepressed behaviour" endophenotype)
showed significant hypoperfusion in left temporal pole (-
18,8,-36; T = 4.31, cluster size = 807), right dorsolateral
frontal cortex (10,52,8; T = 4.86, cluster size = 506), and
insula (-54,10,16; T = 4.18, cluster size = 256; 36,-30,8; T
= 4.45, cluster size = 275; 42,4,0; T = 3.56, cluster size =
51).
Clinical diagnosis and Latent Class comparisons
Finally, LCs were compared to the clinical diagnosis.
In Table 5 and Figure 4, the analysis of proportion of clin-
ical diagnoses within LCs was reported. bvFTD patients
mainly belong to LC1 (the pseudomanic behaviour endo-
phenotype), but there was a high overlap of different clin-
ical diagnoses in LC2 and LC3.
Discussion
The aim of this study was to establish a data-driven nosol-
ogy and to provide the neuroimaging correlates in FTLD.
This analysis suggested a division into three groups,
clearly distinguished by specific functional hypoperfusion
patterns.
Table 2: Neuropsychological assessment in FTLD patients.
Diagnosis BvFTD SD PNFA CBD PSP
Short story 8.3 ± 4.7 (41.4) 5.5 ± 1.3 (80.0) 5.1 ± 3.4 (83.3) 8.5 ± 4.9 (31.5) 9.7 ± 2.9 (47.3)
Raven Colored Progressive Matrices 21.7 ± 5.7 (26.8) 29.2 ± 5.2 (0.0) 26.1 ± 3.8 (0.0) 23.0 ± 6.0 (25.0) 24.3 ± 6.4 (31.5)
Rey Complex Figure, Copy 23.5 ± 10.5 (48.7) 26.5 ± 12.9 (40.0) 34.3 ± 1.1 (0.0) 22.1 ± 10.5 (68.7) 24.5 ± 9.2 (64.7)
Rey Complex Figure, Recall 11.6 ± 7.2 (43.9) 11.4 ± 3.0 (60.0) 16.0 ± 1.3 (0.0) 12.0 ± 5.6 (56.2) 14.9 ± 6.8 (63.1)
Verbal fluency 22.1 ± 11.1 (34.1) 19.6 ± 10.0 (40.0) 10.5 ± 1.7 (66.6) 23.4 ± 11.5 (31.2) 23.8 ± 9.3 (26.3)
Category Fluency 25.5 ± 11.2 (48.7) 18.0 ± 10.2 (60.0) 23.7 ± 13.7 (50.0) 32.1 ± 10.8 (18.7) 30.5 ± 6.7 (26.3)
Digit Span 5.5 ± 1.5 (4.8) 5.7 ± 0.7 (0.0) 4.0 ± 2.3 (16.7) 5.2 ± 1.1 (6.2) 5.7 ± 0.9 (0.0)
Token Test 28.4 ± 5.6 (2.1) 25.3 ± 3.1 (40.0) 26.3 ± 2.2 (16.0) 28.9 ± 5.5 (25.0) 32.2 ± 3.0 (10.5)
Trail Making A 158.8 ± 171.2 (39.0) 224.4 ± 235.6 (40.0) 309.1 ± 220.9 (66.6) 130.9 ± 154.6 (31.2) 123.6 ± 114.4 (63.1)
Trail Making B 275.0 ± 151.9 (39.0) 285.8 ± 165.6 (60.0) 281.3 ± 149.8 (50.0) 292.5 ± 175.7 (43.7) 251.3 ± 145.9 (47.3)
De Renzi Imitation Test 66.2 ± 8.2 (9.7) 71.3 ± 1.1 (0.0) 62.5 ± 10.6 (33.3) 53.7 ± 16.1 (43.8) 66.6 ± 5.2 (0.0)
bvFTD: behavioural variant of Frontotemporal Dementia; SD: Semantic Dementia; PNFA: Progressive Non-Fluent Aphasia; CBD: Corticobasal 
Degeneration; PSP: Progressive Supranuclear Palsy. Percentage of subjects with pathological scoring according to Italian normative data between 
brackets (percentage > 50% are underlined)Page 6 of 12
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Maps of significant voxels representing regions of hypoperfusion in FTLD patients according to clinical diagnosis, superimposed to reference T1-weighted MRI imageFigur  1
Maps of significant voxels representing regions of hypoperfusion in FTLD patients according to clinical diagno-
sis, superimposed to reference T1-weighted MRI image. bvFTD: behavioural variant of Frontotemporal Dementia (first 
row), SD: Semantic Dementia (second row), PNFA: Progressive Non-Fluent Aphasia (third row), PSP: Progressive Supranu-
clear Palsy (fourth row), and CBD: Corticobasal Degeneration (fifth row) patient subgroups are reported. Statistical threshold, 
P < 0.001, T ≥ 3.99, minimum cluster size = 50 voxels. Neurological convention: left is on the left side and vice versa.
BMC Neurology 2007, 7:9 http://www.biomedcentral.com/1471-2377/7/9The clinical, pathological and genetic heterogeneity of
FTLD accounts for its present nosological controversy, and
opens the question of whether this generic label repre-
sents a unique syndrome best viewed as complex, or if it
includes different and distinct entities.
At present, FTLD classification relies upon clinical symp-
toms at disease presentation, but the convergence of the
different clinical pictures in overlapping syndromes and
their poor concordance with pathology, made of the FTLD
clinical diagnosis a challenging problem [9]. We currently
differentiate FTLD in bvFTD, SD, PNFA, PSP, CBD, and
these clinical distinctions may also have functional corre-
spondences (see Figure 1). The mismatch, however,
between clinical pictures and pathology makes the present
classification largely unsatisfactory. This suggests the need
of an alternative explanation to describe FTDL discrete
clinical presentations.
Table 3: Goodness of fit statistics, and class frequencies for LPA models from 1 to 5 latent classes.
LC (1) LC (2) LC (3) LC (4) LC (5)
Log-L (H0) -29663.70 -2636.05 -2554.08 -2512.92 -2507.12
n parameters 32 49 66 83 100
AIC 5991.4 5370.1 5240.2 5191.8 5214.2
BIC 6073.8 5493.7 5406.6 5401.1 5466.4
Entropy 0.92 0.951 0.963 0.945
Class frequencies (%)
n1 92 (100) 44 (47.8) 17 (18.5) 8 (8.7) 28 (30.4)
n2 48 (52.2) 38 (41.3) 12 (13.0) 3 (3.3)
n3 37 (40.2) 33 (35.9) 17 (18.5)
n4 39 (42.4) 29 (31.5)
n5 15 (16.3)
LPA: Latent Profile Analysis; LC: Latent Class; Log-L (H0): Log-likelihood of hypothesized model (H0)
AIC: Akaike's Information Criterion (= -2 × model log-likelihood + 2 × number of model parameters); BIC: Bayesian Information Criterion (= -2 × 
model log-likelihood + log(n) × number of model parameters)
Table 4: Maximum Likelihood estimates (MLE) of the mean profiles, and common of the clinical and neuropsychological assessment 
variables across the selected three LCs (*)
Latent class means (#)
Variable LC1 (n = 18) LC2 (n = 41) LC3 (n = 38) Common variances
BADL (lost functions) 2.444 0.366 0.184 1.049
IADL (lost functions) 5.111 1.244 0.632 2.858
NPI 31.556 8.707 11.211 0.847
FBI, A 19.833 7.610 6.289 4.025
FBI, B 14.056 2.122 3.711 1.524
Neuropsychological Assessment
MMSE 19.283 20.917 25.790 2.198
Short Story (ES) 0.889 0.537 1.632 1.551
Colored Progressive Matrices (ES) 0.722 0.683 2.632 0.807
Rey Figure, Copy (ES) 0.278 0.585 2.211 2.089
Rey Figure, Recall (ES) 0.333 1.000 2.895 2.116
Fluency, Letter (ES) 1.000 1.000 2.184 2.122
Fluency, Category (ES) 0.222 0.756 2.632 1.279
Digit PNFAn (ES) 2.111 2.220 3.211 2.466
Token Test (ES) 0.722 0.927 2.895 1.682
Trial-Making, Test A (ES) 0.278 0.463 3.158 1.165
Trial-Making, Test B (ES) 0.278 0.366 2.105 1.226
BADL: Basic Activities of Daily Living; IADL: Instrumental Activities of Daily Living; NPI: Neuropsychiatry Inventory; FBI: Frontal Behavioural 
Inventory. ES: Equivalent Scores (according to Italian normative data, range 0–4; 0 = poor performance to 4 better performance). (*) All MLEs were 
statistically significant (i.e different to zero using t-test: P < 0.05), and expressed mean values.
(#) Statistically significant (P < 0.05) means differences between LC1 vs. (LC2, LC3) are bold-underline, while between (LC1, LC2) vs. LC3 are 
underline.Page 8 of 12
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BMC Neurology 2007, 7:9 http://www.biomedcentral.com/1471-2377/7/9In this study, we tried to disentangle these issues, employ-
ing the open statistical approach provided by Latent Pro-
file Analysis and applying it to a large sample of FTLD
patients. Our aim was to single out which, and how many
clinical presentations could be generated by a statistical
analysis blinded to an extended cognitive/behavioural
data set in FTLD patients.
Latent Profile Analysis posits that a heterogeneous group
can be reduced to several homogeneous subgroups
through evaluating and then minimizing the pairwise cor-
relations among responses across multiple continuous
variables. Thus, Latent Profile Analysis is capable of deter-
mining the number and composition of unobserved
latent classes that produce observed data. This approach is
particularly useful when there is evidence that certain
symptoms co-aggregate at above normal levels (that is,
symptoms that are beyond what is usually seen in patients
who present certain syndrome patterns) to form distinct
clusters.
In the present study, cognitive performance, the severity
of behavioural symptoms, and functional impairment
were examined in a large sample of FTLD patients, and
three distinct clusters were detected, named "pseu-
domanic behaviour", "cognitive" and "pseudodepressed
behaviour".
The first, i.e. LC1, was represented by greater behavioural
disturbances, such as dishinibition and abnormal social
conduct, as evidenced in FBI and NPI scores. The concom-
itant impairment in BADL and IADL in these patients is
therefore the result of inadequacy or disinhibition rather
than the consequence of the cognitive decline. The second
LC2 profile was underscored by a "cognitive" endopheno-
type, mainly characterized by executive dysfunction. The
third LC3 showed better performances in neuropsycho-
logical test scores compared to the other two LCs, and sub-
tle behavioural abnormalities, mainly represented by
depressive symptoms.
It is noteworthy to mention that motor impairment,
measured by UPDRS-III scale, was not used to define the
latent classes, and was uncorrelated with either cognitive
or behavioural profiles, suggesting an independence
between motor aspects and cognitive/behavioural per-
formances.
Thus, referring to the nosology of FTLD, our data-driven
approach identified three clinical syndromes. In the same
vein, a recent experimental work applied a similar
approach, i.e. Factor Analysis, to clarify the classification
issue in Progressive Aphasia [2].
As a second goal of the present study, the SPECT imaging
modality and Statistical Parametric Mapping (SPM2) were
used to identify functional correspondence of the FTLD as
generated by Latent Profile Analysis. The SPM2 method
was applied to verify if the generated LCs depended on
different stage of the disease, or if they were the expression
of three different endophenotypes.
The three clusters obtained by Latent Profile Analysis were
underscored by specific functional correlates. Hypoper-
fusion in frontal medial and orbitobasal cortex was found
in the "pseudomanic behaviour" endophenotype, subcor-
tical brain region hypoperfusion was detected in the "cog-
nitive" endophenotype, hypoperfusion in the dorsolateral
frontal cortex and insula characterised the "pseudode-
pressed behaviour" endophenotype (Figure 3). These data
provide evidence that specific neurofunctional-symptom
cluster relationship can be delineated in patients with
FTLD, thus excluding that these latent classes represent
different disease stages.
Interestingly, the pseudomanic and pseudodepressed
endophenotypes paralleled previous behavioural and
metabolic findings reported in a group of FTLD patients
Scatter-plot of FTLD patients labelled according to generated three Latent ClassesFigure 2
Scatter-plot of FTLD patients labelled according to 
generated three Latent Classes. y axis: values of behav-
ioural disturbances (measured by Frontal Behavioural Inven-
tory Scale, FBI-A plus FBI-B,); x axis: values of cognitive 
deficits (cognitive sum, i.e. the sum of Equivalent Scores of all 
the neuropsychological tests included in the assessment, the 
higher the value the better the performance; see Table 4). 
The centroid (0;0) represents the overall mean profile; com-
pared to the average value of the whole sample, LC1 patients 
have higher cognitive sum values (i.e. less severe cognitive 
impairment); while LC2 and LC3 patients have lower cogni-
tive sum values (i.e. more severe cognitive impairment); vice 
versa the behavioural deficit values are higher in the LC1 than 
in the LC2 and LC3 patients.Page 9 of 12
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BMC Neurology 2007, 7:9 http://www.biomedcentral.com/1471-2377/7/9[34]. The main subset of symptoms in "cognitive" endo-
phenotye, such as executive dysfunctions, can well be
attributed to impairment of the dorsolateral-frontal cir-
cuit at the basal ganglia level; in fact, when data were
explored at a lower threshold (P < 0.005), not only sub-
cortical brain regions, but also dorsolateral frontal cortex
was involved (-32,58,16; T = 2.87, cluster size = 101).
Table 5: FTLD diagnosis distribution according to Latent Classes.
LC/Diagnosis BvFTD (n = 41) SD (n = 5) PNFA (n = 6) CBD (n = 16) PSP (n = 29)
LC1 (n = 18) 77.8 (14) 5.6 (1) 0.0 (0) 5.6 (1) 11.2 (2)
LC2 (n = 41) 31.7 (13) 4.9 (2) 9.8 (4) 17.1 (7) 36.6 (15)
LC3 (n = 38) 36.8 (14) 5.3 (2) 5.3 (2) 21.1 (8) 31.5 (12)
TOTAL 42.3 (41) 5.2 (5) 6.2 (6) 16.5 (16) 29.9 (29)
LC: Latent Class; bvFTD: behavioural variant of Frontotemporal Dementia; SD: Semantic Dementia; PNFA: Slowly Progressive Aphasia; CBD: 
Corticobasal Degeneration; PSP: Progressive Supranuclear Palsy.
Results are expressed as conditional Latent Classes percentage and number of patients between brackets.
Maps of significant voxels representing regions of hypoperfusion in FTLD patients according to the three Latent Classes, super-imposed to reference T1-weight d MRI imageFigur  3
Maps of significant voxels representing regions of hypoperfusion in FTLD patients according to the three 
Latent Classes, superimposed to reference T1-weighted MRI image. LC: Latent Class. LC1 (first row), LC2 (second 
row), and LC3 (third row) patient subgroups are reported. Statistical threshold, P < 0.001, T ≥ 3.40, minimum cluster size = 50 
voxels. Neurological convention: left is on the left side and vice versa.Page 10 of 12
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BMC Neurology 2007, 7:9 http://www.biomedcentral.com/1471-2377/7/9An increasing number of studies evaluating brain tissue
volume and metabolic function in dementia demonstrate
that regional tissue loss, or hypometabolism, correlates
with specific cognitive or behavioural impairment in
FTLD [35,4]. FTLD patients, however, had profuse cogni-
tive and behavioural abnormalities, thus suggesting that
all these symptoms could have had a common neurofunc-
tional basis [36]. To date, few studies in either dementia
or focal lesions has systematically examined the func-
tional correlates of clustered behavioural and neuropsy-
chological symptoms, such as here conducted by Latent
Profile Analysis, instead of individual symptoms. We also
performed the SPM2 analysis on the basis of pre-defined
criteria (see Figure 1), confirming previous neuroimaging
findings [7,10,11].
The present results suggest that FTLD syndromes lie on a
continuum rather then existing as independence entities.
Latent Profile Analysis approach demonstrated that FTLD
can be summarised into three different clinical categories
with a poor concordance with the usual clinical classifica-
tion. Indeed, despite of a higher level of concordance in
diagnosis distribution between LC1 and bvFTD, the other
two LCs, i.e. LC2 and LC3, are otherwise variably repre-
sented (see Figure 4).
It has been recently reported that there is a convergence of
the syndromes in the course of the disease [9]. In the
future, it would be interesting to evaluate the clinical and
overlapping aspects of these clusters over time.
Notwithstanding, approaches based on standardised
assessment, similar or different to those presented in this
study, are crucial for a clear-cut description of the wide
range of features, both behavioural and cognitive, that
may characterise FTLD and related disorders.
The results of this study should be replicated in other sam-
ple size cross-sectional studies, and these should be per-
formed to determine if the same endophenotypes remain
stable across studies. We indeed acknowledge the need of
prognostic outcomes to prove the usefulness of the
present scheme. Moreover, neuropathological confirma-
tion would be necessary to further understand the rela-
tionship between clinical and neuropathological
endophenotypes. In an era of treatment that targets dis-
ease-mechanism, it would be desirable that Latent Profile
Analysis will be used to further discriminate molecular/
genetic determinants of FTLD pathology.
Conclusion
In conclusions, among the mild FTLD variants, character-
ised by a wide clinical overlap, specific clinical and func-
tional neural networks may be identified at the beginning
of the disease. Further longitudinal studies will be
devoted to analysing the evolution of such clusters in
order to delineate the pattern of disease progression.
Abbreviations
FTLD: Frontotemporal Lobar Degeneration; SPECT: Sin-
gle Photon Emission Tomography; bvFTD: behavioural
variant of frontotemporal dementia; SD: Semantic
Dementia; PNFA: Progressive Non-fluent Aphasia; PSP:
Progressive Supranuclear Palsy; CBD: Corticobasal
Degeneration; LPA: Latent Profile Analysis.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
BB conceived of the study, and participated in its design
and coordination and in the draft of the manuscript; MG
participated in the design of the study, performed statisti-
cal analysis and revised the manuscript critically for intel-
lectual content; DP participated in the design of the study,
in neuroimaging analyses and revised the manuscript crit-
Proportion of each clinical diagnosis across the three Latent ClassesFigure 4
Proportion of each clinical diagnosis across the three 
Latent Classes. LC: Latent Class; bvFTD: behavioural vari-
ant of Frontotemporal Dementia, SD: Semantic Dementia, 
PNFA: Progressive Non-Fluent Aphasia, PSP: Progressive 
Supranuclear Palsy, and CBD: Corticobasal Degeneration.Page 11 of 12
(page number not for citation purposes)
BMC Neurology 2007, 7:9 http://www.biomedcentral.com/1471-2377/7/9ically for intellectual content; CA and AA performed the
clinical evaluation of the patients and have made substan-
tial contribution to interpretation of data; BP has made
substantial contributions in the acquisition of the data;
MDL has been involved in the study design and in revising
it critically for important intellectual content; AP con-
ceived of the study, and participated in its design and in
coordination and drafted the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
The authors wish to thank the patients and their families for taking part into 
this study. The authors are indebted to Andrea Rudiak for editing the man-
uscript.
References
1. Kertesz A, Hillis A, Munoz D: Frontotemporal degeneration,
Pick's Disease, Pick Complex and Ravel.  Ann Neurol 2003,
54(S5):1-2.
2. Knibb JA, Xuareb JH, Patterson K, Hodges JR: Clinical and patho-
logical characterisation of progressive aphasia.  Ann Neurol
2006, 59:156-65.
3. Kertesz A, Hudson L, Mackenzie IR, Munoz DG: The pathology
and nosology of primary progressive aphasia.  Neurology 1994,
44:2065-72.
4. Rosen HJ, Allison SC, Schauer GF, Gorno-Tempini ML, Weiner MW,
Miller BL: Neuroanatomical correlates of behavioural disor-
ders in dementia.  Brain 2005, 128:2612-25.
5. Hodges JR, Davies RR, Xuereb JH, Casey B, Broe M, Bak TH, Kril JJ,
Halliday GM: Clinicopathological correlates in frontotemporal
dementia.  Ann Neurol 2004, 56:399-406.
6. Padovani A, Borroni B, Brambati SM, Agosti C, Broli M, Alonso R,
Scifo P, Bellelli G, Alberici A, Gasparotti R, Perani D: Diffusion ten-
sor imaging and voxel based morphometry study in early
progressive supranuclear palsy.  J Neurol Neurosurg Psychiatry
2006, 77:457-63.
7. Miller BL, Seeley WW, Mychack P, Rosen HJ, Mena I, Boone K: Neu-
roanatomy of the self: evidence from patients with fronto-
temporal dementia.  Neurology 2001, 11:817-21.
8. Shi J, Shaw CL, Du Plessis D, Richardson AM, Bailey KL, Julien C, Stop-
ford C, Thompson J, Varma A, Craufurd D, Tian J, Pickering-Brown S,
Neary D, Snowden JS, Mann DM: Histopathological changes
underlying frontotemporal lobar degeneration with clinico-
pathological correlation.  Acta Neuropathol 2005, 110:501-12.
9. Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG: The evo-
lution and pathology of frontotemporal dementia.  Brain 2005,
128:1996-2005.
10. Gorno-Tempini ML, Dronkers NF, Rankin KP, Ogar JM, Phengrasamy
L, Rosen HJ, Johnson JK, Weiner MW, Miller BL: Cognition and
anatomy in three variants of primary progressive aphasia.
Ann Neurol 2004, 55:335-46.
11. Chapman SB, Bonte FJ, Wong SB, Zientz JN, Hynan LS, Harris TS,
Gorman AR, Roney CA, Lipton AM: Convergence of connected
language and SPECT in variants of frontotemporal lobar
degeneration.  Alzheimer Dis Assoc Disord 2005, 19:202-13.
12. Liu W, Miller BL, Kramer JH, Rankin K, Wyss-Coray C, Gearhart R,
Phengrasamy L, Weiner M, Rosen HJ: Behavioral disorders in the
frontal and temporal variants of frontotemporal dementia.
Neurology 2004, 62:742-48.
13. Bartholomew DJ, Knott M: Latent Variable Models and Factor Analysis
London: Arnold; 1999. 
14. Neary D, Snowden J, Gustafson L, Passant U, Stuss D, Black S, Freed-
man M, Kertesz A, Robert P, Albert M, Boone K, Miller B, Cummings
J, Benson D: Frontotemporal Lobar degeneration: a consen-
sus on clinical diagnostic criteria.  Neurology 1998, 51:1546-54.
15. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Tro-
janowski JQ, Work Group on Frontotemporal Dementia and Pick's
Disease: Clinical and pathological diagnosis of frontotemporal
dementia: report of the Work Group on Frontotemporal
Dementia and Pick's Disease.  Arch Neurol 2001, 58:1803-09.
16. Louis ED, Lynch T, Marder K, Fahn S: Reliability of patient com-
pletion of the historical section of the United Parkinson's
Disease Rating Scale.  Mov Disord 1996, 11:185-92.
17. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State": a prac-
tical method for grading the cognitive state of patients for
the clinician.  J Psychiatr Res 1975, 12:189-98.
18. Bingham WC, Burke HR, Murray S: Raven's Progressive Matrices:
construct validity.  J Psycgol 1966, 62:205-9.
19. Isaacs B, Kennie AT: The Set test as an aid to the detection of
dementia in old people.  Br J Psychiatry 1973, 123:467-70.
20. Wolf-Klein GP, Silverstone FA, Levy AP, Brod MS: Screening for
Alzheimer's disease by clock drawing.  J Am Geriatr Soc 1989,
37:730-34.
21. Loring DW, Martin RC, Meador KJ: Psychometric construnction
of the Rey-Osterrieth Complex Figure.  Arch Clin Neuropsych
1990, 5:1-14.
22. Babcock H, Levy L: The measurement of mental efficiency of
mental functioning (revised examination).  In Test and manual
of directions Chicago: CH Stoelting; 1940. 
23. Blackburn HL, Benton AL: Revised administration and scoring of
the digit span test.  J Consult Psychol 1957, 21:139-43.
24. Reitan RM: Validity of the Trail Making Test as an indicator of
organic brain damage.  Perceptual and motor skills 1958, 8:271-76.
25. De Renzi E, Vignolo LA: The Token Test: a sensitive test to
detect receptive disturbances in aphasics.  Brain 1962,
85:665-78.
26. De Renzi E, Motti F, Nichelli P: Imitating gestures. A quantita-
tive approach to ideomotor apraxia.  Arch Neurol 1980, 37:6-10.
27. Lawton MP, Broody EM: Assessment of older people: self-main-
taining and instrumental activities of daily living.  The Gerontol-
ogist 1969, 9:179-86.
28. Sheikh K, Smith DS, Meade TW, Goldenberg E, Brennan PJ, Kinsella
G: Repeatibility and validity of a modified Activities of Daily
Living (ADL) Index in studies of chronic disability.  Int Rehabil
Med 1979, 1:51-58.
29. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA,
Gornbein J: The Neuropsychiatric Inventory: comprehensive
assessment of psychopathology in dementia.  Neurology 1994,
44:2308-14.
30. Kertesz A, Nadkarni N, Davidson W, Thomas AW: The Frontal
Behavioral Inventory in the differential diagnosis of fronto-
temporal dementia.  J Int Neuropsychol Soc 2000, 6:460-68.
31. Friston KJ, Holmes AP, Worsley KJ, Poline J-B, Frith CD, Frackowiack
RSJ: Statistical parametric maps in functional imaging: a gen-
eral linear approach.  Hum Brain Mapp 1995, 2:189-210.
32. Burnham KP, Anderson DR: Model Selection and Inference.  In A
Practical Information Theoretic Approach 2nd edition. Springer-Verlag,
New York; 2002. 
33. Muthén LK, Muthén BO: How to use a Monte Carlo study to
decide on sample size and determine power.  Structural Equa-
tion Modeling 2002, 9:599-620.
34. Franceschi M, Anchisi D, Pelati O, Zuffi M, Matarrese M, Moresco RM,
Fazio F, Perani D: Glucose metabolism and serotonin recep-
tors in the frontotemporal lobe degeneration.  Ann Neurol
2005, 57:216-25.
35. Nadeau SE: Alzheimer's disease as a window to neural mech-
anisms of cognition.  Neurology 2003, 61:1470-71.
36. Salmon E, Kerrouche N, Herholz K, Perani D, Holthoff V, Beuthien-
Baumann B, Degueldre C, Lemaire C, Luxen A, Baron JC, Collette F,
Garraux G: Decomposition of metabolic brain clusters in the
frontal variant of frontotemporal dementia.  Neuroimage 2006,
30:871-78.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2377/7/9/prepubPage 12 of 12
(page number not for citation purposes)
